01:07am Friday 23 June 2017

Can Anti-Inflammatory Therapies Be Effective Against Epilepsy?

The latest evidence on one particular chemokine of interest, CCL2, and its potential role in human epilepsy are the focus of an article in DNA and Cell Biology, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free for download on the DNA and Cell Biology website until August 6, 2016.

In “Epilepsy, Seizures, and Inflammation: Role of the C-C Motif Ligand 2 Chemokine,” Yuri Bozzi, National Research Council, Pisa, and Matteo Caleo University of Trento, Italy, provide a comprehensive review of the research demonstrating the link between both systemic and brain inflammation and epileptic seizures. Based on established evidence that CCL2 mediates the seizure-promoting effects of inflammation, and that selectively blocking either the synthesis of CCL2 or its receptor in animal models of epilepsy suppresses inflammation-induced seizures, the researchers suggest that drugs already in use for several human disorders that interfere with CCL2 signaling might be effective for treating epilepsy that is not controlled with current therapies.

“The targeted therapeutic approach to attack recruitment of inflammatory cells to the site of neuronal hyperactivity by preventing the chemoattractant molecule CCL2 from recruiting circulating cells is very promising,” says Carol Shoshkes Reiss, PhD, Editor-in-Chief of DNA and Cell Biology, and Professor, Departments of Biology and Neural Science, and Global Public Health at New York University, NY. “I hope these studies can be translated from the bench to the bedside.”


Share on:
or:

MORE FROM Brain Diseases

Health news